Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization

Journal of Korean Medical Science

Volumn 19, Issue 5, 2004, Pages 682-687

  Lee, Ji Young ^a   Park, Young Nyun ^b   Uhm, Kyung Ok ^a   Park, Soo Yeun ^c   Park, Sun Hwa ^a  

^a Korea University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

Cholangiocarcinoma; Chromosome Aberrations; Comparative Genomic Hybridization; Polymerase Chain Reaction

Indexed keywords

DNA; OLIGONUCLEOTIDE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CARCINOMA; CHROMOSOME 11Q; CHROMOSOME 15Q; CHROMOSOME 16P; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 5P; CHROMOSOME 6P; CHROMOSOME 7P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME IDENTIFICATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTRAHEPATIC CHOLANGIOCARCINOMA; MALE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE;

EID: 7544245923     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.5.682     Document Type: Article

References (40)

1. Forozan F, Karhu R, Kononen J, Kallioniemi A, Kallioniemi OP. Genome screening by comparative genomic hybridization. Trends Genet 1997; 13: 405-9.
2. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A. Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 1992; 13: 718-25.
3. Huang Q, Schantz SP, Rao PH, Mo J, McCormick SA, Chaganti RS. Improving degenerate oligonucleotide primed PCR-comparative genomic hybridization for analysis of DNA copy number changes in tumors. Genes Chromosomes Cancer 2000; 28: 395-403.
4. Kim YI, Park CK, Kim JR, Chang JJ. Primary malignant epithelial neoplasms of the liver. J Korea Cancer Assoc 1980; 12: 33-53.
5. Pederson LC, Buchsbaum DJ, Vickers SM, Kancharla SR, Mayo MS, Curiel DT, Stackhouse MA. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4325-32.
6. Holzinger F, Z'graggen K, Buchler MW. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann Oncol 1999; 10 (Suppl 4): S122-6.
7. Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2001; 130: 22-8.
8. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypemethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002; 37: 633-9.
9. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoint in cholangiocarcinoma cell line. Genes Chromosomes Cancer 1990; 2: 300-10.
10. Kim DG, Park SY, You KR, Lee GB, Kim H, Moon WS, Chun YH, Park SH. Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Gene Chromosomes Cancer 2001; 30: 48-56.
11. Kang YK, Kim YI, Kim WH. Allelotype analysis of intrahepatic cholangiocarcinoma. Mod Pathol 2000; 13: 627-31.
12. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999; 79: 477-83.
13. Terada T, Ashida K, Endo K, Hone S, Maeta H, Matsunaga Y, Takashima K, Ohta T, Kitamura Y. C-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 1998; 33: 325-31.
14. INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47: 721-7.
15. Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Visakorpi T, Isola J. Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer 1997; 18: 94-101.
16. Kim GJ, Cho SJ, Won NH, Sung JM, Kim H, Chun YH, Park SH. Genomic imbalances in Korean hepatocellular carcinoma. Cancer Genet Cytogenet 2003; 142: 129-33.
17. el-Rifai W, Larramendy ML, Bjorkqvist AM, Hemmer S, Knuutila S. Optimazation of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest 1997; 77: 699-700.
18. Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, Andren-Sandberg A, Kallioniemi OP, Johansson B. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p and 17q and losses of 18q, 9p, and 15q inpancreatic cancer. Genes Chromosomes Cancer 1997; 20: 383-91.
19. Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997; 19: 161-9.
20. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998; 21: 177-84.
21. Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E, Look AT. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 1995; 25: 130-8.
22. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-8.
23. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, Cloutier T, Kuo WL, Yaswen P, Dairkee S, Giovanola J, Hutchinson GB, Isola J, Kallioniemi OP, Palazzolo M, Martin C, Ericsson C, Pinkel D, Gray JW, Albertson D, Li WB. Positional cloning of ZNF217 and NABCl: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998; 95: 8703-8.
24. Ghadima BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999; 154: 525-36.
25. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20: 189-93.
26. Ukita Y, Kato M, Terada T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 2002; 36: 780-5.
27. Meenakshi A, Kumar RS, Siva Kumar N, Genesh V. Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: a preliminary study. Hum Antibodies 2002; 11: 73-7.
28. Takai S, Long JE, Yamada K, Miki T. Chromosomal localization of the human ECT2 proto-oncogene to 3q26.1→q26.2 by somatic cell analysis and fluorescence in situ hybridization. Genomics 1995; 27: 220-2.
29. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet 1999; 21: 99-102.
30. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003; 1004: 318-27.
31. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res 2001; 61: 4122-9.
32. Feldman BJ, Reid TR, Cleary ML. Pim1 cooperates with E2a-Pbxl to facilitate the progression of thymic lymphomas in transgenic mice. Oncogene 1997; 15: 2735-42.
33. Inaba T, Matsushime H, Valentine M, Roussel MF, Sherr CJ, Look AT. Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 1992; 13: 565-74.
34. Akervall JA, Jin Y, Wennerberg JP, Zatterstrom UK, Kjellen E, Mertens F, Willen R, Mandahl N, Heim S, Mitelman F. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 1995; 76: 853-9.
35. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998; 20: 473-9.
36. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 1995; 90: 43-50.
37. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 1995; 159: 83-96.
38. Piao Z, Park C, Park JH, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer 1998; 75: 29-33.
39. Momoi H, Okabe H, Kamikawa T, Satoh S, Ikai I, Yamamoto M, Nakagawara A, Shimahara Y, Yamaoka Y, Fukumoto M. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res 2001; 7: 2648-55.
40. Li SP, Wang HY, Li JQ, Zhang CQ, Feng QS, Huang P, Yu XJ, Huang LX, Liang QW, Zeng YX. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol 2001; 34: 840-9.